{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hong SD"],"funding":["National Research Foundation of Korea (NRF)"],"pagination":["11733"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11545925"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25(21)"],"pubmed_abstract":["Ovarian cancer is the deadliest gynecologic cancer. Although human epidermal growth factor receptor-2 (HER2) overexpression, a poor prognostic molecular marker in ovarian cancer, is found in almost 30% of ovarian cancer cases, there are no established therapies for HER2-overexpressing ovarian cancer. In this study, we investigated the efficacy of combined samfenet, a biosimilar compound of trastuzumab, and natural killer (NK) cells in preclinical model of HER2-overexpressing ovarian cancer. Firstly, we screened the HER2 expression in three ovarian cancer cell lines and eight ovarian cancer patient-derived tumor xenograft (PDTX) samples. Then, immunohistochemistry and silver in situ hybridization (SISH) were performed following clinical criteria. HER2-overexpressing cells exhibited the high"],"journal":["International journal of molecular sciences"],"pubmed_title":["Trastuzumab-Mediated Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Enhances Natural Killer Cell Cytotoxicity in HER2-Overexpressing Ovarian Cancer."],"pmcid":["PMC11545925"],"funding_grant_id":["NRF-2021R1C1C1006882"],"pubmed_authors":["Park SM","Kim TH","Kang MS","Ghosh M","Baek YS","Katuwal NB","Moon YW","Hong SD","Lee SR"],"additional_accession":[]},"is_claimable":false,"name":"Trastuzumab-Mediated Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Enhances Natural Killer Cell Cytotoxicity in HER2-Overexpressing Ovarian Cancer.","description":"Ovarian cancer is the deadliest gynecologic cancer. Although human epidermal growth factor receptor-2 (HER2) overexpression, a poor prognostic molecular marker in ovarian cancer, is found in almost 30% of ovarian cancer cases, there are no established therapies for HER2-overexpressing ovarian cancer. In this study, we investigated the efficacy of combined samfenet, a biosimilar compound of trastuzumab, and natural killer (NK) cells in preclinical model of HER2-overexpressing ovarian cancer. Firstly, we screened the HER2 expression in three ovarian cancer cell lines and eight ovarian cancer patient-derived tumor xenograft (PDTX) samples. Then, immunohistochemistry and silver in situ hybridization (SISH) were performed following clinical criteria. HER2-overexpressing cells exhibited the high","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-04-22T03:20:02.08Z","creation":"2025-04-19T17:27:00.374Z"},"accession":"S-EPMC11545925","cross_references":{"pubmed":["39519282"],"doi":["10.3390/ijms252111733"]}}